Pyrazolo[1,5-a]pyridine-3-carbonitrile, 6-[(2-hydroxyethyl)amino]-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]- manufacturers
- RET-IN-15
-
- $2270.00
-
2026-05-21
- CAS:2643375-86-2
- Purity:
- Supply Ability: 10g
|
| | Pyrazolo[1,5-a]pyridine-3-carbonitrile, 6-[(2-hydroxyethyl)amino]-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]- Basic information |
| | Pyrazolo[1,5-a]pyridine-3-carbonitrile, 6-[(2-hydroxyethyl)amino]-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]- Chemical Properties |
| density | 1.43±0.1 g/cm3(Predicted) | | pka | 14.48±0.10(Predicted) |
| | Pyrazolo[1,5-a]pyridine-3-carbonitrile, 6-[(2-hydroxyethyl)amino]-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]- Usage And Synthesis |
| Uses | RET-IN-15 is a rearranged during transfection (RET) kinase inhibitor extracted from patent WO2021115457A1 compound 51. RET-IN-15 can be used for the research of cancer[1]. | | References | [1] Chen HM, et, al. Pyrazolo[1,5-a]pyridine compound, preparation method therefor and use thereof. WO2021115457A1. |
| | Pyrazolo[1,5-a]pyridine-3-carbonitrile, 6-[(2-hydroxyethyl)amino]-4-[6-[6-[(6-methoxy-3-pyridinyl)methyl]-3,6-diazabicyclo[3.1.1]hept-3-yl]-3-pyridinyl]- Preparation Products And Raw materials |
|